8 results on '"Villalobos, Triana"'
Search Results
2. Growth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational study
- Author
-
Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología, López Siguero, Juan P., Martínez Aedo, María J., Bermúdez de la Vega, José Antonio, Bosh Muñoz, Jordi, Lechuga Sancho, Alfonso M., Villalobos, Triana, Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología, López Siguero, Juan P., Martínez Aedo, María J., Bermúdez de la Vega, José Antonio, Bosh Muñoz, Jordi, Lechuga Sancho, Alfonso M., and Villalobos, Triana more...
- Abstract
Objective :In children born small for gestational age (SGA), the relationship betweengrowth hormone (GH) treatment and insulin resistance (IR) has only been investigated fora short period, necessitating a longer observation period. This study aimed to evaluate thelong‐term (10 years) effect of GH to SGA‐children on IR and safety during treatment.Design:This was a multicenter observational study.Patients:SGA‐children who received GH treatment in Spain (stratified by Tanner‐stage and age at GH onset [two groups:≤6 years old or >6 years old]).Measurements:The analysed variables (yearly measures) included auxologic, meta-bolic (insulin‐like growth factor‐1 (IGF‐1), height velocity [HV], weight and homeo-static model assessment‐IR [HOMA‐IR]) and safety data. Data were collectedprospectively (since the study approval: 2007) and retrospectively (since the initia-tion of GH treatment: 2005–2007).Results:A total of 389 SGA children (369 Tanner‐I) were recruited from 27 centres.The mean age (standard deviation) of the children at GH treatment onset was 7.2(2.8) years old. IGF‐1 (standard deviation score [SDS]) and HOMA‐IR values tendedto increase until the sixth year of GH‐treatment, with significant differences beingobserved only during the first year, while these remained stable in the later years(within normal ranges). Height (SDS) increased significantly (basal:−3.0; tenthyear:−1.13), and the maximum HV (SDS) occurred during the first year (2.75 ± 2.39).Conclusions:HOMA‐IR values increased significantly in SGA‐children during thefirst year of GH‐treatment, remained stable and were within normal ranges in allcases. Our 10‐year data suggests that long‐term GH treatment does not promote IRand is well‐tolerated, safe and effective. more...
- Published
- 2022
Catalog
3. Growth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational study
- Author
-
López-Siguero, Juan P, Martínez-Aedo, Maria J, Bermúdez de la Vega, Jose Antonio, Bosch-Muñoz, Jordi, Lechuga-Sancho, Alfonso M, Villalobos, Triana, SGA Study Investigator Collaborative Group, and Universidad de Sevilla. Departamento de Farmacología, Pediatría y Radiología more...
- Subjects
Efficacy ,Human Growth Hormone ,Endocrinology, Diabetes and Metabolism ,Long‐termfollow‐up ,Homeostatic model assessment ,Infant, Newborn ,long-term follow-up ,Insulin resistance ,Gestational Age ,Small for gestational age ,Body Height ,Endocrinology ,Child, Preschool ,Infant, Small for Gestational Age ,Humans ,Safety ,Insulin Resistance ,Insulin-Like Growth Factor I ,Child ,Growth hormone ,Retrospective Studies - Abstract
Objective: In children born small for gestational age (SGA), the relationship between growth hormone (GH) treatment and insulin resistance (IR) has only been investigated for a short period, necessitating a longer observation period. This study aimed to evaluate the long-term (10 years) effect of GH to SGA-children on IR and safety during treatment. Design: This was a multicenter observational study. Patients: SGA-children who received GH treatment in Spain (stratified by Tanner-stage and age at GH onset [two groups: ≤6 years old or >6 years old]). Measurements: The analysed variables (yearly measures) included auxologic, metabolic (insulin-like growth factor-1 (IGF-1), height velocity [HV], weight and homeostatic model assessment-IR [HOMA-IR]) and safety data. Data were collected prospectively (since the study approval: 2007) and retrospectively (since the initiation of GH treatment: 2005–2007). Results: A total of 389 SGA children (369 Tanner-I) were recruited from 27 centres. The mean age (standard deviation) of the children at GH treatment onset was 7.2 (2.8) years old. IGF-1 (standard deviation score [SDS]) and HOMA-IR values tended to increase until the sixth year of GH-treatment, with significant differences being observed only during the first year, while these remained stable in the later years (within normal ranges). Height (SDS) increased significantly (basal: −3.0; tenth year: −1.13), and the maximum HV (SDS) occurred during the first year (2.75 ± 2.39). Conclusions: HOMA-IR values increased significantly in SGA-children during the first year of GH-treatment, remained stable and were within normal ranges in all cases. Our 10-year data suggests that long-term GH treatment does not promote IR and is well-tolerated, safe and effective. The present work was financed by Merck, S.L.U. more...
- Published
- 2021
4. Growth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF‐1 levels, while improving height in patients small for gestational age A long‐term observational study.
- Author
-
López‐Siguero, Juan P., Martínez‐Aedo, Maria J., Bermúdez de la Vega, Jose Antonio, Bosch‐Muñoz, Jordi, Lechuga‐Sancho, Alfonso M., and Villalobos, Triana
- Subjects
SMALL for gestational age ,SOMATOTROPIN ,INSULIN resistance ,PITUITARY dwarfism ,SCIENTIFIC observation ,INSULIN therapy - Abstract
Objective: In children born small for gestational age (SGA), the relationship between growth hormone (GH) treatment and insulin resistance (IR) has only been investigated for a short period, necessitating a longer observation period. This study aimed to evaluate the long‐term (10 years) effect of GH to SGA‐children on IR and safety during treatment. Design: This was a multicenter observational study. Patients: SGA‐children who received GH treatment in Spain (stratified by Tanner‐stage and age at GH onset [two groups: ≤6 years old or >6 years old]). Measurements: The analysed variables (yearly measures) included auxologic, metabolic (insulin‐like growth factor‐1 (IGF‐1), height velocity [HV], weight and homeostatic model assessment‐IR [HOMA‐IR]) and safety data. Data were collected prospectively (since the study approval: 2007) and retrospectively (since the initiation of GH treatment: 2005–2007). Results: A total of 389 SGA children (369 Tanner‐I) were recruited from 27 centres. The mean age (standard deviation) of the children at GH treatment onset was 7.2 (2.8) years old. IGF‐1 (standard deviation score [SDS]) and HOMA‐IR values tended to increase until the sixth year of GH‐treatment, with significant differences being observed only during the first year, while these remained stable in the later years (within normal ranges). Height (SDS) increased significantly (basal: −3.0; tenth year: −1.13), and the maximum HV (SDS) occurred during the first year (2.75 ± 2.39). Conclusions: HOMA‐IR values increased significantly in SGA‐children during the first year of GH‐treatment, remained stable and were within normal ranges in all cases. Our 10‐year data suggests that long‐term GH treatment does not promote IR and is well‐tolerated, safe and effective. [ABSTRACT FROM AUTHOR] more...
- Published
- 2022
- Full Text
- View/download PDF
5. Insulin resistance in children born small for gestational age treated with growth hormone. An observational study
- Author
-
López Siguero, Juan P., Martínez-Aedo, Maria J., Bermúdez de la Vega, José A., Bosch Muñoz, Jordi, Lechuga-Sancho, Alfonso M., Fernandez-González, Ana, and Villalobos, Triana
- Subjects
HOMA ,Sensibilidad a insulina ,Hormona de crecimiento - Abstract
Background. In children born small for gestational age (SGA), the relationship between growth hormone (GH) treatment and insulin resistance [IR] has been investigated for a short-term period, being necessary a longer observation. Objectives. Evaluate the long-term (10 years) effect of the GH administered to SGA-children on IR and the safety during treatment. Methods. Multicenter observational study in SGA children receiving GH treatment in Spain (stratified by Tanner stage and age at GH onset [two groups: ≤6 years; >6 years]). Analyzed variables (yearly) included auxologic (growth velocity [GV]), metabolic (IGF-1, homeostatic model assessment- IR [HOMA-IR]), and safety ones. Data were collected prospectively since study approval (2007) and retrospectively from GH treatment onset (2005- 2007). Results. Interim analysis (6 years' follow-up) of 389 SGA children (369 Tanner I) from 27 centers. Mean age (SD) at GH treatment onset): 7.2 (3.1) years. IGF-1 (SDS) and HOMA-IR tended to increase until the sixth year with significant differences at the first year, and remaining stable thereafter (within normal ranges). Height (SDS) increased significantly (basal: -3.0; sixth year: -1.5); being the maximum GV at the first year (8.60 cm/year, with higher values in the ≤6 years group). Twenty-one adverse events were reported, two of them serious: type 2 diabetes, and osteonecrosis. Conclusions. The HOMA-IR increased significantly in SGA children during the first year of GH treatment, remaining stable later on, within normal ranges in any case. Our sixth-year data suggest that long-term GH treatment does not promote IR, is well tolerated, safe, and effective Antecedentes. En niños pequeños para su edad gestacional (PEG), se ha investigado la relación entre el tratamiento con hormona de crecimiento (GH) y la resistencia a insulina [RI] a corto plazo, siendo necesario un período mayor. Objetivos. Evaluación del efecto a largo plazo (10 años) de la GH administrada a niños PEG sobre la RI y la seguridad durante el tratamiento. Métodos. Estudio multicéntrico observacional en niños PEG tratados con GH en España, según estadio Tanner y edad al inicio del tratamiento (dos grupos: ≤6 años y >6 años). Las variables analizadas (mediciones anuales) incluyeron parámetros auxológicos (velocidad de crecimiento [VC]), metabólicos (IGF-1, RI [HOMA-IR]) y de seguridad. Datos recogidos prospectivamente, desde aprobación del estudio (2007), y retrospectivamente desde el inicio GH (2005-2007). Resultados. Análisis intermedio (seguimiento a 6 años) de 389 pacientes PEG (369 Tanner I) de 27 centros. Edad media (DE) al inicio GH: 7,2 (3,1) años. IGF-1 (SDS) y HOMA-IR tendieron a aumentar hasta el año 6, con diferencias significativas en el primer año y permaneciendo posteriormente estables (manteniéndose en rangos normales). La talla (SDS) aumentó significativamente (basal: -3,0; año 6: -1,5), con VC máxima en el primer año (8,60 cm/año, mayor en el grupo ≤6 años). Se comunicaron 21 acontecimientos adversos, 2 graves: diabetes mellitus 2 y osteonecrosis. Conclusiones. En niños PEG, el tratamiento con GH aumenta significativamente el índice HOMA-IR en el primer año, permaneciendo posteriormente estable, y siempre dentro de la normalidad. Los datos a 6 años sugieren que este tratamiento a largo plazo no induce RI, es bien tolerado, seguro y efectivo. more...
- Published
- 2020
6. PSX-9 Sexual Behavior of Rams Exposed to Anovulatory Ewes Receiving Different Doses of P4
- Author
-
Villalobos-Triana, C, primary, Guillen-Muñoz, J, additional, Luna-Orozco, J, additional, Yong-Wong, S, additional, Véliz-Deras, F, additional, De Santiago-Miramontes, A, additional, and Contreras-Villarreal, V, additional more...
- Published
- 2018
- Full Text
- View/download PDF
7. Insulin resistance in children born small for gestational age treated with growth hormone. An observational study
- Author
-
López Siguero, Juan P., Martínez-Aedo, Maria J., Bermúdez de la Vega, José A., Bosch Muñoz, Jordi, Lechuga-Sancho, Alfonso M., Fernandez-González, Ana, and Villalobos, Triana
- Subjects
HOMA ,Sensibilidad a insulina ,Hormona de crecimiento
8. PSX-9 Sexual Behavior of Rams Exposed to Anovulatory Ewes Receiving Different Doses of P4
- Author
-
S Yong-Wong, J.M. Guillen-Muñoz, Juan Ramón Luna-Orozco, A De Santiago-Miramontes, Francisco G. Véliz-Deras, C Villalobos-Triana, and Viridiana Contreras-Villarreal
- Subjects
Abstracts ,Sexual behavior ,Genetics ,Physiology ,Animal Science and Zoology ,General Medicine ,Food Science - Abstract
The aim of the present research was to evaluate the sexual behavior of male sheep during the sexual resting period while exposed to anovulatory females treated with an intravaginal sponge impregnated with progesterone (P4) in northern Mexico. The study took place in northern Mexico (26º N), during the month of March, multiracial rams (n=8, 24–48 mo.) were divided in two homogeneous groups (n=4 each) regarding live weight, body condition score, scrotal circumference and smell, and randomly allocated in two experimental treatments: 1) Males exposed to anovulatory females (n=20) with 20mg of P4 sponges (M20), and 2) Males exposed to anovulatory females (n=20) with 10mg of P4 sponges (M10). Sexual behavior tests were performed in both groups of males by experienced technicians (2 h x 2 d, on days 11 and 12 of the experimental period. Sexual behaviors included flehmen, ano-genital sniffing, approaches and mount attempts. The sexual behavior data was divided in appetitive sexual behaviors [ASB: flehmen, approaches, sniffing (bodily or ano-genital) approaches and vocalizing]; consummatory sexual behaviors (CSB: mount attempts, mounting with erection and mounting with ejaculation). The sexual behavior data were evaluated by X(2), using the SYSAT 12.0 statistics program. The largest ASB was shown by the M10 group (64% vs 35%, P0.05) was observed between experimental groups. These findings suggest that males improve their appetitive sexual behaviors (ano-genital sniffing and flehmen), when exposed to ewes treated with 20mg of progesterone. more...
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.